Alyami Mohammad H, Alyami Hamad S, Alshehri Abdullah A, Alsharif Wijdan K, Shaikh Ibrahim Ahmed, Algahtani Thamer S
Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 66462, Saudi Arabia.
National Centre for Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
Gels. 2022 Jul 21;8(7):456. doi: 10.3390/gels8070456.
The present study aims to design and develop a nanoemulgel formulation of Tamoxifen citrate (TAM), a water-insoluble, potent anticancer drug, using the spontaneous emulsification method to improve topical delivery, achieve high accumulation at the tumour site, and spare the healthy tissues. The oil-based selection was related to the TAM solubility, while the surfactant and co-surfactant were chosen based on the droplets' thermodynamic stability and size. Afterwards, a pseudo-ternary phase diagram was built for the most promising formulation using two oils, olive and sesame, with a varied mix of Tween 40 as the surfactant and Trascutol HP as the co-surfactant (S), by the optimisation of experiments. The nanoemulsion (NE) formulations that were prepared were found to have an average droplet size of 41.77 ± 1.23 nm and 188.37 ± 3.53 nm, with suitable thermodynamic stability and physicochemical properties. Both olive and sesame oils are natural food additives due to their associated antioxidant effects; therefore, they showed no toxicity profile on breast cell lines (MCF-7, ATCC number HTB-22). The TAM-NE preparations revealed a prolonged and doublings superior cumulative percentage of in vitro release of TAM compared to TAM plain gel suspension over 24 h. The release data suggested that the Higuchi model was the best fitting kinetical model for the developed formulations of NE1, NE9, and NE18. The extended release of the drug as well as an acceptable amount of the drug permeated TAM via nanogel preparations suggested that nanoemulgel (NEG) is suitable for the topical delivery of TAM in breast cancer management. Thus, this work suggests that a nanogel of TAM can improve anticancer properties and reduce systemic adverse effects compared to a suspension preparation of TAM when applied in the treatment of breast cancer.
本研究旨在设计并开发一种柠檬酸他莫昔芬(TAM)的纳米乳凝胶制剂。TAM是一种水不溶性强效抗癌药物,采用自发乳化法以改善局部给药,实现肿瘤部位的高蓄积,并保护健康组织。油相的选择与TAM的溶解度有关,而表面活性剂和助表面活性剂则根据液滴的热力学稳定性和大小来选择。之后,通过实验优化,使用橄榄油和芝麻油这两种油,以吐温40作为表面活性剂、二乙二醇单乙醚(Transcutol HP)作为助表面活性剂(S),构建了最有前景制剂的伪三元相图。所制备的纳米乳(NE)制剂平均液滴尺寸分别为41.77±1.23 nm和188.37±3.53 nm,具有合适的热力学稳定性和理化性质。橄榄油和芝麻油均为天然食品添加剂,具有抗氧化作用;因此,它们对乳腺癌细胞系(MCF-7,ATCC编号HTB-22)无毒性。与TAM普通凝胶悬液相比,TAM-NE制剂在24小时内TAM的体外释放累积百分比延长且翻倍。释放数据表明,Higuchi模型最适合NE1、NE9和NE18的开发制剂的动力学模型。药物的缓释以及通过纳米凝胶制剂渗透的TAM药物量可接受,表明纳米乳凝胶(NEG)适用于乳腺癌治疗中TAM的局部给药。因此,这项工作表明,与TAM悬浮制剂相比,TAM纳米凝胶在应用于乳腺癌治疗时可改善抗癌性能并减少全身不良反应。